ApprovalJul 24, 2026
FDA approval — GSK Canada Receives Approval For Shingrix Zoster Vaccine In Prefilled Syringe▸
high impact
ApprovalJul 22, 2026
FDA approval — FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule▸
high impact
Data −Jul 17, 2026
Negative data — GSK shares are trading lower after the company announced that it will cease further development of Camlipixant as a chr…▸
high impact
Data +Jul 10, 2026
Positive data — GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership▸
high impact
DealJul 08, 2026
Deal — GSK Terminates Collaboration, License Agreement With Alector, Effective Jan. 2, 2027; Alector Repays $10.429M▸
medium impact
DealJun 24, 2026
Deal — GSK Commences Tender Offer To Acquire Nuvalent At $124/Share▸
medium impact
ApprovalJun 17, 2026
FDA approval — GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs▸
high impact
DealJun 09, 2026
Deal — GSK Enters Agreement To Acquire Nuvalent For $10.6B At $124 Per Share, A 40% Premium To Last Closing Price▸
medium impact
EarningsMay 22, 2026
FY 2025 report-0.3%muted
DealMay 07, 2026
Deal — Halozyme Therapeutics Signs License Agreement With GSK For ENHANZE Drug Delivery Technology To Develop, Commercialize S…▸
medium impact
AdComApr 28, 2026
FDA advisory — GSK's Bepirovirsen Receives FDA Priority Review And Breakthrough Therapy Designation For Chronic Hepatitis B With PDUFA…▸
high impact
DealApr 27, 2026
Deal — Alfasigma Completes License Agreement With GSK To Develop, Manufacture, Commercialise Linerixibat▸
medium impact
EarningsNov 12, 2025
FY 2024 report-0.3%muted
EarningsMay 12, 2025
FY 2024 report+0.5%muted
EarningsNov 13, 2024
FY 2023 report-3.0%muted